File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage

TitleUlcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage
Authors
Issue Date2000
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2000, v. 14 n. 8, p. 1071-1076 How to Cite?
AbstractAim: To study the efficacy of a 2-week anti-Helicobacter therapy in the healing of H. pylori-associated bleeding peptic ulcers. Methods: Omeprazole 20 mg, clarithromycin 500 mg and amoxycillin 1 g, twice daily, were given for 2 weeks to 180 patients with H. pylori-associated bleeding peptic ulcers. Endoscopy was repeated 4 weeks after the eradication therapy to assess healing of the peptic ulcers. Results: Repeat endoscopies were performed in 168 patients (42 gastric ulcer and 126 duodenal ulcer) who followed the protocol. Thirty-eight patients with bleeding gastric ulcers and 124 patients with bleeding duodenal ulcers healed 4 weeks after treatment (per protocol analysis; gastric ulcer: 91% vs. duodenal ulcer: 98%; P = 0.035). No patients who were compliant to the study medications suffered from re-bleeding. Stepwise discriminant analysis demonstrated that small ulcers (< 15 mm) and the presence of duodenal ulcers best predicted healing of the peptic ulcers. Conclusions: Ulcer-healing drugs should be continued after a 2-week course of omeprazole-containing anti-Helicobacter therapy for gastric ulcers and large peptic ulcers that have bled, but can be omitted in most patients with a bleeding duodenal ulcer.
Persistent Identifierhttp://hdl.handle.net/10722/162388
ISSN
2023 Impact Factor: 6.6
2023 SCImago Journal Rankings: 2.794
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, KCen_US
dc.contributor.authorHui, WMen_US
dc.contributor.authorWong, BCYen_US
dc.contributor.authorHu, WHCen_US
dc.contributor.authorLam, SKen_US
dc.date.accessioned2012-09-05T05:19:30Z-
dc.date.available2012-09-05T05:19:30Z-
dc.date.issued2000en_US
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2000, v. 14 n. 8, p. 1071-1076en_US
dc.identifier.issn0269-2813en_US
dc.identifier.urihttp://hdl.handle.net/10722/162388-
dc.description.abstractAim: To study the efficacy of a 2-week anti-Helicobacter therapy in the healing of H. pylori-associated bleeding peptic ulcers. Methods: Omeprazole 20 mg, clarithromycin 500 mg and amoxycillin 1 g, twice daily, were given for 2 weeks to 180 patients with H. pylori-associated bleeding peptic ulcers. Endoscopy was repeated 4 weeks after the eradication therapy to assess healing of the peptic ulcers. Results: Repeat endoscopies were performed in 168 patients (42 gastric ulcer and 126 duodenal ulcer) who followed the protocol. Thirty-eight patients with bleeding gastric ulcers and 124 patients with bleeding duodenal ulcers healed 4 weeks after treatment (per protocol analysis; gastric ulcer: 91% vs. duodenal ulcer: 98%; P = 0.035). No patients who were compliant to the study medications suffered from re-bleeding. Stepwise discriminant analysis demonstrated that small ulcers (< 15 mm) and the presence of duodenal ulcers best predicted healing of the peptic ulcers. Conclusions: Ulcer-healing drugs should be continued after a 2-week course of omeprazole-containing anti-Helicobacter therapy for gastric ulcers and large peptic ulcers that have bled, but can be omitted in most patients with a bleeding duodenal ulcer.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_US
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAmoxicillin - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshAnti-Bacterial Agents - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshAnti-Ulcer Agents - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshClarithromycin - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshDuodenal Ulcer - Complications - Drug Therapy - Microbiologyen_US
dc.subject.meshEndoscopyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHelicobacter Infections - Complications - Pathologyen_US
dc.subject.meshHelicobacter Pylorien_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOmeprazole - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshPenicillins - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshPeptic Ulcer Hemorrhage - Drug Therapy - Pathologyen_US
dc.subject.meshStomach Ulcer - Complications - Drug Therapy - Microbiologyen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleUlcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhageen_US
dc.typeArticleen_US
dc.identifier.emailWong, BCY:bcywong@hku.hken_US
dc.identifier.authorityWong, BCY=rp00429en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1046/j.1365-2036.2000.00803.xen_US
dc.identifier.pmid10930902-
dc.identifier.scopuseid_2-s2.0-0033852738en_US
dc.identifier.hkuros72213-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033852738&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume14en_US
dc.identifier.issue8en_US
dc.identifier.spage1071en_US
dc.identifier.epage1076en_US
dc.identifier.isiWOS:000089157100013-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLai, KC=7402135595en_US
dc.identifier.scopusauthoridHui, WM=7103196477en_US
dc.identifier.scopusauthoridWong, BCY=7402023340en_US
dc.identifier.scopusauthoridHu, WHC=25932937100en_US
dc.identifier.scopusauthoridLam, SK=7402279473en_US
dc.identifier.issnl0269-2813-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats